CBP plans to deploy a new capability that will “migrate all ACE Portal Periodic Monthly Statement (PMS) features to the modernized ACE Portal” on April 13, it said in an update to its ACE development and deployment calendar. That will include “the ability to designate participants, activate participants, and schedule upcoming statements.” Users will “no longer have access to PMS tools in the legacy ACE portal” at that time, CBP said.
CBP is in the process of selecting accreditors for its continuing education requirement for customs brokers, said Shari McCann, director of commercial operations for CBP's Office of Trade, during a session at the CBP Trade Facilitation and Cargo Security Summit on March 28.
The Commerce Department last week issued new antidumping and countervailing duty regulations, which, most notably, lifted the prohibition on the consideration of transnational subsidies in CVD cases (see 2403210070).
PHILADELPHIA -- Getting the funding for ACE 2.0 is the biggest challenge, the executive director of CBP's trade transformation office said. He said the agency was unsuccessful in the budgetary process, and asked industry to lobby their representatives for funding.
The International Trade Commission published notices in the March 27 Federal Register on the following AD/CVD injury, Section 337 patent or other trade proceedings (any notices that warrant a more detailed summary will be in another ITT article):
The International Trade Commission is proposing to permanently adopt its COVID-19 era regulation that waived the need for paper filings of confidential and public documents in safeguard, antidumping and countervailing duty, and Section 337 proceedings. In a proposed rule released March 28, the ITC, at the request of the ITC Trial Lawyers Association and the Customs and International Trade Bar Association, proposed eliminating the requirement for paper copy submissions, except for complaints and complaint supplements and amendments in Section 337 cases. The regulation also removes "gender-specific language" found in the ITC's rules.
The Commerce Department published notices in the Federal Register March 27 on the following AD/CV duty proceedings (any notices that announce changes to AD/CV duty rates, scope, affected firms or effective dates will be detailed in another ITT article):
The Commerce Department has released amended final results of the antidumping duty administrative review on cold-rolled steel flat products from South Korea (A-580-881) that were used to set final assessments of AD on importers for subject merchandise entered Sept. 1, 2021, through Aug. 31, 2022 (see 2402220060). The amendment came as the result of a ministerial error allegation from Steel Dynamics, Inc. Commerce said it agreed with the allegation, which pointed out that in calculating a countervailing duty export subsidy offset for Hyundai Steel Company, Commerce adjusted Hyundai's U.S. price by 4% instead of by the intended 0.04%. The correction results in a change to two AD rates published Feb. 23 in the original final results. The new rates are effective March 28.
The Commerce Department will soon suspend liquidation and impose countervailing duty cash deposit requirements on imports of frozen warmwater shrimp from Ecuador, India and Vietnam, but will not at this time suspend liquidation or set duties on frozen warmwater shrimp from Indonesia after finding no countervailable subsidization for that country, it said in a fact sheet March 26. The agency's preliminary determinations set CVD rates at 1.69% to 13.41% for Ecuadorian companies, 3.89% to 4.72% for Indian companies, and 2.84% to 196.41% for Vietnamese companies. If Commerce continues to find no countervailable subsidization for Indonesia in its final determination, the agency will not issue a CVD order on Indonesia. CVD suspension of liquidation and cash deposit requirements for Ecuador, India and Vietnam will take effect for entries on or after the date of publication of the preliminary determinations in the Federal Register, which should occur in the coming days.
On March 26, the FDA posted new and revised versions of the following Import Alerts (after not having posted new ones for a number of days) on the detention without physical examination of: